The Food and Drug Administration (FDA) has requested Endo Pharmaceuticals to take their opioid painkiller, Opana ER, off the market. The drug has been linked to various disease outbreaks as well has heavy opioid abuse through users who crush and inject the pill. FDA Commissioner, Scott Gottlieb, explained that the request comes from a renewed focus on ending the opioid epidemic in the United States. Endo Pharmaceuticals said, in a statement, that the company is reviewing the agency’s request and will consider all avenues for the drug moving forward. Read the full article here.